Mobile Menu
truCrowd - Equity Crowdfunding

KhemoSafe Inc

Follow
INVEST

39dd02hh

Time left to invest


$1,927

amount committed 

$10k - $250k

funding goal 

Regulation CF

exemption used 

$2,750,000

pre money valuation 

$99.75

min investment 

14

investors 


Security Type
Common Stock
Shares of Common Stock
at $1.33 per Share

Pitch

Who are we

 

 

Problem

The federal agency, National Institute for Occupational Therapy and Health (NIOSH) estimates that over 8 million healthcare workers, patients and the environment are being exposed to hazardous waste vapors from chemotherapy medications.

 

The ‘yellow bins’ currently being used at hospitals to collect hazardous waste materials do not have an effective vapor containment mechanism. Therefore, odorless toxic air is constantly emanating from these bins until they are properly removed.

 

Healthcare workers and patients are unaware of the amount of hazardous vapors they are breathing in on a daily basis.

 

 

 

Solution

Our motion-censored, hands-free device is designed to make the user feel safe and to avoid surface contamination. 

The user waves their hand over the bin, the lid will open and the medication is dropped into a plastic-lined container. Once the lid closes, the plastic bag is sealed and no toxic vapors are released back into the environment. 

 

On the back end, the unit uses machine-learning algorithms to calculate waste data collection information that results in cost-saving measures for the hospital. 

 

 

 

Achievement & Traction

Khemosafe is new to the market, it is the only company that has an answer to a long-standing problem.  

 

The USP General Chapter <800>, was developed by USP Compounding Expert Committee, the USP Compounding with Hazardous Drug Expert Panel, the FDA, the CDC, and NIOSH.   USP <800> provides standards for safe handling of hazardous drugs to minimize the risk of exposure to healthcare personnel, patients, and the environment. 

 

As of December 1, 2019, there are NO OFFICIAL RULES or GUIDELINES on how to properly dispose of hazardous waste.

 

We are directing our efforts to healthcare workers that handle chemotherapy medications and we are expanding our demographic to all healthcare workers currently dealing with the global pandemic COVID-19.

 

When Personal Protective Equipment (PPE's), like gloves, gowns, and masks are disposed of, the virus remains active on the surface for several hours. 

 

The Khemosafe unit will decrease that level of exposure by sealing the polyethylene bag immediately after the PPEs are disposed of and preventing the virus from re-entering the environment.

 

 

 

Market

TOTAL U.S. HAZARDOUS WASTE REVENUE: $4 Billion

OUT OF WHICH, ONCOLOGY WASTE REVENUE IS: $1.2 Billion

 

 

 

Competition

 

Khemosafe is the only company that has designed a hazardous waste unit that employs IoT technology to thwart exposure of vapors and collect relevant data to employ prescriptive and predictive analytics.

 

 

 

Business Model

We will be using a B2B strategy by licensing the unit to health institutions for a monthly or annual fee.  

 

Khemosafe will provide institutions with monthly reports on how much waste they have generated - useful for sustainability and monitoring waste management costs.

 

 

 

Team

 

 

 

 

 

Use of Funds

Khemosafe Inc is seeking to raise $250,000.00.  

The funds will be used to finalize and execute the prototype, and get the product into manufacturing. 

 

Additionally, a white-paper study is going to be conducted on the chemotherapy and immunosuppressant drug Cytoxan. The study will examine aerosolized contact surface samples plus create an airflow model to calculate the trajectory of hazardous waste vapors of this common medication.

 

These studies help researchers better understand how to continue creating life-saving measures for individuals handling hazardous equipment and drugs.

 

 

COVID Relief

This offering is being conducted on an expedited basis due to circumstances relating to COVID-19 and pursuant to the SEC’s temporary COVID-19 regulatory relief set out in Regulation Crowdfunding §227.201(z).

 

Offering maximum

In reliance on Reg. CF Rule 201(z)(3) of this relief, financial information certified by the principal executive officer of the issuer has been provided instead of financial statements reviewed by a public accountant that is independent of the issuer, in setting the offering maximum of $250,000.

 

Updates


No updates, yet. Stay tuned.

Q&A


You must be logged in to be able to post a question.


Documents

Start-up Valuation Download
Offering Statement Download

Other Disclosures

Read the Form C filed with the SEC for other important disclosures, like financial statements, Directors, Officers, shareholders with more than 20% of voting rights, and more.
Irregular Use of Proceeds
The Company may make Irregular Use of Proceeds. Such Irregular Use of Proceeds, which may be in material amounts in excess of $10,000, may include by way of example and not limitation: Vendor payments and salary made to management, business associates, relatives, related parties and/or affiliates thereof; expenses labeled "Administration Expenses" that are not strictly for administrative purposes; expenses labeled "Travel and Entertainment"; and expenses that are for the purposes of intercompany debt or back payments.

Without limiting the above, the Company may elect to vary from the proposed use of funds as circumstances or assessments of circumstances following the closing change.
Special Note Regarding Forward-Looking Statements
This offering contains forward-looking statements within the meaning of the federal securities laws. We caution investors that any forward-looking statements presented in this offering, or which management may make orally or in writing from time to time, are based on the Company’s beliefs and assumptions made by, and information currently available to, the Company. When used, the words “anticipate,” “believe,” “expect,” “intend,” “may,” “might,” “plan,” “estimate,” “project,” “should,” “will,” “would,” “result” and similar expressions, which do not relate solely to historical matters, are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties and factors that are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. While forward-looking statements reflect the Company’s good faith belief when made, they are not guarantees of future performance. The Company expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this offering may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publically release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.
up

Back to top